Canada Intravenous Iron Drugs Market Size & Outlook
Canada intravenous iron drugs market, 2018-2030 (US$M)
Related Markets
Canada intravenous iron drugs market highlights
- The Canada intravenous iron drugs market generated a revenue of USD 83.8 million in 2022 and is expected to reach USD 214.7 million by 2030.
- The Canada market is expected to grow at a CAGR of 12.5% from 2023 to 2030.
- In terms of segment, iron sucrose was the largest revenue generating product in 2022.
- Other Product is the most lucrative product segment registering the fastest growth during the forecast period.
Intravenous iron drugs market data book summary
| Market revenue in 2022 | USD 83.8 million |
| Market revenue in 2030 | USD 214.7 million |
| Growth rate | 12.5% (CAGR from 2023 to 2030) |
| Largest segment | Iron sucrose |
| Fastest growing segment | Other Product |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Other Product |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, Canada accounted for 2.9% of the global intravenous iron drugs market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. intravenous iron drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 214.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Iron sucrose was the largest segment with a revenue share of 51.43% in 2022. Horizon Databook has segmented the Canada intravenous iron drugs market based on iron dextran, iron sucrose, other product covering the revenue growth of each sub-segment from 2018 to 2030.
As per Canadian Organ Replacement Register Annual Statistics 2019, over 50,000 people in Canada are being treated for kidney failure. As per the same source, around 58% of people with end-stage kidney disease are treated with dialysis. IV iron drug is considered as an effective treatment module for patients with dialysis-associated CKD.
Data from Government of Canada reported that nearly 300,000 people in the country could have celiac disease, but many remain undiagnosed. Gluten-containing food, if consumed by people with undiagnosed celiac disease, impairs the ability to absorb many nutrients, including iron.
Therefore, rise in the number of undiagnosed celiac disease in the country drives the demand for IV iron drugs. Government of Canada also reported that around 669,600 Canadian people 40 years & older live with diagnosed heart failure. Heart failure also results in iron deficiency, thereby driving the need for treatment with iron drugs.
Reasons to subscribe to Canada intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada intravenous iron drugs market size, by product, 2018-2030 (US$M)
Canada Intravenous Iron Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
